PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Trial ID or NCT#

NCT01617954

Status

not recruiting iconNOT RECRUITING

Purpose

This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Official Title

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Eligibility Criteria

Ages Eligible for Study: 18 Years to 90 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Women with histologically proven invasive stage I-II, node negative, hormone receptor positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score (18-30) - ≥ 18 years of age at time of consent - Written informed consent
Exclusion Criteria:
  1. - Insufficient tissue remaining for Mammaprint FFPE - Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria - Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy

Investigator(s)

Mark Pegram
Medical oncologist, Breast specialist
Susy Yuan-Huey Hung Professor
Kristin Jensen

Contact us to find out if this trial is right for you.

CONTACT

Annabel Castaneda
650-498-7977